Nasal-nanotechnology: revolution for efficient therapeutics delivery
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
CONTEXT: In recent years, nanotechnology-based delivery systems have gained interest to overcome the problems of restricted absorption of therapeutic agents from the nasal cavity, depending upon the physicochemical properties of the drug and physiological properties of the human nose. OBJECTIVE: The well-tolerated and non-invasive nasal drug delivery when combined with the nanotechnology-based novel formulations and carriers, opens the way for the effective systemic and brain targeting delivery of various therapeutic agents. To accomplish competent drug delivery, it is imperative to recognize the interactions among the nanomaterials and the nasal biological environment, targeting cell-surface receptors, drug release, multiple drug administration, stability of therapeutic agents and molecular mechanisms of cell signaling involved in patho-biology of the disease under consideration. METHODS: Quite a few systems have been successfully formulated using nanomaterials for intranasal (IN) delivery. Carbon nanotubes (CNTs), chitosan, polylactic-co-glycolic acid (PLGA) and PLGA-based nanosystems have also been studied in vitro and in vivo for the delivery of several therapeutic agents which shown promising concentrations in the brain after nasal administration. RESULTS AND CONCLUSION: The use of nanomaterials including peptide-based nanotubes and nanogels (NGs) for vaccine delivery via nasal route is a new approach to control the disease progression. In this review, the recent developments in nanotechnology utilized for nasal drug delivery have been discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Transport of drugs from the nasal cavity to the central nervous system
Illum, L. (2000) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(00)00087-7 · Cited by 907 · cited 1×
“When a drug administered through nasal route it may enter into the blood of general circulation, may permeate the brain directly or in some cases may follow both pathways (Illum, 2000).”
BackgroundNanoparticles for direct nose-to-brain delivery of drugs
Mistry, A., Stolnik, S., & Illum, L. (2009) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2009.06.019 · Cited by 734
Intranasal Drug Delivery: How, Why and What For?
Pires, A., Fortuna, A., Alves, G., & Falcão, A. (2009) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j3nc79 · Cited by 641
Nasal mucociliary clearance as a factor in nasal drug delivery
Marttin, E., Schipper, N. G. M., Verhoef, J. C., & Merkus, F. W. H. M. (1998) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(97)00059-8 · Cited by 469 · cited 1×
“However, high viscosity of formulations hampers the regular functions like ciliary beating or mucociliary clearance and as a consequence modifies the permeability of drugs (Schipper et al., 1991; Merkus & Schusler-van Hees, 1992; Mason et al., 1995; Merkus et al., 1998).”
BackgroundIntranasal nanoemulsion based brain targeting drug delivery system of risperidone
Kumar, M., Misra, A., Babbar, A. K., Mishra, A. K., Mishra, P., & Pathak, K. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2008.03.029 · Cited by 435
Direct access of drugs to the human brain after intranasal drug administration?
Merkus, P., Guchelaar, H.-J., Bosch, D. A., & Merkus, F. W. H. M. (2003) · Neurology · doi:10.1212/01.wnl.0000067993.60735.77 · Cited by 81 · cited 3×
“This is illustrated by the process of nasal absorption of L-tyrosine which increases with drug concentration in nasal perfusion experiments (Boek et al., 1999; Merkus et al., 2001; Costantino et al., 2007).”
BackgroundCurrent advances in delivery of biotherapeutics across the blood-brain barrier.
Rajadhyaksha, M., Boyden, T., Liras, J., El-Kattan, A., & Brodfuehrer, J. (2011) · Current Drug Discovery Technologies · doi:10.2174/157016311795563866 · Cited by 49 · cited 2×
“Even though the clinical potential of this drug administration route still remains controversial, there is substantial curiosity in investigating nasal route for the treatment of many intra-cerebral diseases such as Parkinson’s and Alzheimer’s (Merkus et al., 2003; Illum, 2004; Merkus & van den Berg, 2007; Malerba et…”
BackgroundBahadur, S., & Pathak, K. (2012) · Current Drug Delivery · doi:10.2174/156720112803529792 · Cited by 46
Cited by
Intranasal drug delivery: opportunities and toxicologic challenges during drug development
Keller, L.-A., Merkel, O., & Popp, A. (2022) · Drug Delivery and Translational Research · doi:10.1007/s13346-020-00891-5 · Cited by 591
Wojnarowicz, J., Chudoba, T., & Lojkowski, W. (2020) · Nanomaterials · doi:10.3390/nano10061086 · Cited by 361
Nanosystems in nose-to-brain drug delivery: A review of non-clinical brain targeting studies
Pires, P. C., & Santos, A. O. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.11.047 · Cited by 228
The nasal delivery of nanoencapsulated statins – an approach for brain delivery
Clementino, A., Batger, M., Garrastazu, G., Pozzoli, M., Del Favero, E., Rondelli, V., Gutfilen, B., Barboza, T., Sukkar, M. B., Souza, S. A. L., et al. (2016) · International Journal of Nanomedicine · doi:10.2147/ijn.s119033 · Cited by 81
“53,54 57 The main advantages attributed to these components are their biocompatibility and biodegradability, and in fact, liposomes are still by far the most successful nanomedicines on the market.”
BackgroundHuang, G., Xie, J., Shuai, S., Wei, S., Chen, Y., Guan, Z., Zheng, Q., Yue, P., & Wang, C. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.120182 · Cited by 60
Metadata
- Authors
- Kumar, A., Pandey, A. N., & Jain, S. K.
- Venue
- Drug Delivery
- Publisher
- Informa UK Limited
- Published
- 2014-06-05
- Volume
- 23
- Issue
- 3
- Pages
- 671-683
- ISSN
- 1071-7544 (ISSN-L)
- 1521-0464
- OpenAlex
- W2135195095
- Cited by
- 170
- References
- 8
- FWCI
- 3.27
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Nasal-nanotechnology: revolution for efficient therapeutics delivery. https://app.cochat.ai/papers/10.3109/10717544.2014.920431
- The paper
- Kumar, A., Pandey, A. N., & Jain, S. K. (2016). Nasal-nanotechnology: revolution for efficient therapeutics delivery. Drug Delivery. https://doi.org/10.3109/10717544.2014.920431
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.